NDAOPHTHALMICSOLUTION/DROPS
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
4/8 — Partial
MOXEZA (moxifloxacin hydrochloride) by Teva is 12. First approved in 2010.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOXEZA is a moxifloxacin hydrochloride ophthalmic solution, a fluoroquinolone antibacterial agent administered as eye drops. It demonstrates broad-spectrum antibacterial activity through inhibition of bacterial topoisomerase II and IV, with no phototoxicity potential compared to other fluoroquinolones. The product is indicated for bacterial eye infections and related ophthalmic conditions.
LOE Approaching2.7 years to LOE
With LOE approaching in 2.7 years, the brand team is transitioning from peak revenue management to loss-of-exclusivity planning; career positions may shift toward generic defense, lifecycle management, or portfolio rebalancing.
Mechanism of Action
12.1 Mechanism of Action Moxifloxacin hydrochloride is a member of the fluoroquinolone class of antibacterial agents [see ] . 12.2 Pharmacodynamics Photosensitivity Potential A study of the skin response to ultraviolet (UVA and UVB) and visible radiation conducted in 32 healthy volunteers (8 per…
Worked on MOXEZA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.